ArticleBiotechnology journal2026
A Growth-Coupled Evolutionary Strategy Enhances Heme Biosynthesis in Saccharomyces cerevisiae.
Article in Biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Directed evolution of heme biosynthetic enzymes enabled by a growth-coupled heme biosensor inSynthetic and systems biotechnology · 2026Article
- Systems-Level Metabolic Regulation Strategies of Xylose Metabolism in Saccharomyces cerevisiae.Biotechnology journal · 2026Review
- Integrated Fermentation Engineering Enables High-Level Leghemoglobin Production in Kluyveromyces marxianus via Metabolic Rewiring of Central Carbon Metabolism and Amino Acid Utilization.Biotechnology journal · 2026Article
- A Growth-Coupled Evolutionary Strategy Enhances Heme Biosynthesis in Saccharomyces cerevisiae.Biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Enhancing the nutritional and sensory qualities of microbial single-cell proteins (SCPs) requires strategies to increase heme content in edible microorganisms. We adapted the Growth-Acceleration Targeting Evolution (GATE) platform, initially developed in Corynebacterium glutamicum, for use in Saccharomyces cerevisiae. By engineering a plasmid that connects the heme-responsive CYC1 promoter to the growth-promoting PTH1 gene, we established a feedback loop that links intracellular heme levels to accelerated cell proliferation. After 100 h of continuous culture under growth-selective pressure, we cured out the plasmid to isolate an Evol-GATE strain. Compared to the parental type, Evol-GATE displayed a five-fold increase in intracellular heme, a slight reduction in biomass, and coordinated upregulation of the heme biosynthetic pathway. Transcriptome analysis confirmed increased expression of heme biosynthesis and associated respiratory genes in Evol-GATE. Whole-genome sequencing revealed only a small number of dispersed variants, and no residual plasmid sequences, supporting its classification as a non-GMO mutant. Our results demonstrate that GATE can effectively select yeast mutants with significantly improved heme productivity, providing a promising approach to develop non-GMO SCPs enriched in heme for next-generation meat analogues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.